Metabolon, Inc., a technology company, developing analytical methods and software for biomarker discovery using metabolomic, advancing metabolomics for precision medicine and every area of life sciences research. The firm has developed technology and methodologies for the simultaneous detection and quantification of all small molecules present in a complex biological specimen offering biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon’s powerful proprietary platform enables the rapid discovery of clinically relevant biomarkers enabling a more effective understanding biochemical processes, such as drug action, toxicology, and bioprocess monitoring. Its metabolomics platform is used to develop diagnostics for cancer, amyotropic lateral sclerosis, diabetes, and metabolic diseases. Precision Metabolomics™ is a powerful tool for assessing health and is delivering biomarker discoveries, innovative diagnostic tests, and robust partnerships in genomics and population health initiatives. The firm's expertise is also accelerating research and product development for clients across academia and the pharmaceutical, biotechnology, consumer products, agriculture, pet care and nutrition industries.
